FATE
Fate Therapeutics Inc
2.20$
-6.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.9% | +12.6% | -7.2% | -6.4% | -11.0% | -9.5% | -6.8% | -7.5% | -7.2% | -10.7% | -8.7% | |
| – | -9.0% | +19.0% | -19.0% | -2.8% | -5.9% | -15.0% | -7.2% | -4.0% | -5.7% | -14.0% | -12.0% | |
| – | +25.6% | +189.8% | -69.6% | +2.7% | -4.9% | +24.6% | -8.2% | -1.5% | +14.8% | -15.1% | -18.0% | |
| – | -9.9% | +21.7% | -20.5% | -2.6% | -6.0% | -13.8% | -7.3% | -3.3% | -5.5% | -14.2% | -12.0% | |
| – | +18.7% | -53.0% | +22.1% | +293.8% | -14.2% | -32.0% | -42.0% | -51.1% | +34.3% | -23.1% | -0.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -2.3% | +4.3% | -8.3% | +0.6% | -8.0% | -9.6% | +0.0% | -0.6% | +2.0% | -5.9% | +1.4% | |
| – | -5.4% | +16.1% | -23.3% | +7.6% | +2.9% | -26.9% | +1.8% | -2.0% | +28.3% | -14.9% | +6.2% | |
| – | +3.3% | +3.7% | +3.8% | +3.7% | +7.6% | -11.8% | -13.6% | -16.0% | -4.0% | +3.9% | +3.8% | |
| – | -17.3% | +43.4% | -18.8% | +15.5% | +47.5% | -55.3% | -3.6% | -13.3% | -24.2% | +23.4% | -0.6% | |
| – | -8.5% | +15.7% | -6.8% | -8.7% | -12.0% | -9.5% | -9.4% | -10.4% | -11.5% | -13.3% | -14.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +2.5% | +16.2% | +0.3% | +0.0% | +0.5% | +0.1% | +0.4% | -0.2% | +1.0% | +0.3% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.